Compare RWT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | ZVRA |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | 351 | 61 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 653.2M |
| IPO Year | N/A | 2015 |
| Metric | RWT | ZVRA |
|---|---|---|
| Price | $5.26 | $11.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $6.82 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $26.59 | $37.27 |
| Revenue Next Year | $22.21 | $53.42 |
| P/E Ratio | ★ N/A | $18.34 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $5.00 | $7.16 |
| 52 Week High | $6.97 | $13.16 |
| Indicator | RWT | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 62.20 |
| Support Level | $5.04 | $8.30 |
| Resistance Level | $5.39 | $12.14 |
| Average True Range (ATR) | 0.14 | 0.57 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 4.00 | 69.60 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.